Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host

Joel D. Meyers, James C. Wade, Charles D. Mitchell, Rein Saral, Paul S. Lietman, David T. Durack, Myron J. Levin, Anthony C. Segreti, Henry H. Balfour

Research output: Contribution to journalArticlepeer-review

174 Scopus citations

Abstract

Intravenous acyclovir was evaluated in the treatment of 97 immunocompromised patients with mucocutaneous herpes simplex virus infection in a randomized, double-blind, placebo-controlled trial. Acyclovir recipients had significantly shorter periods of virus shedding (p < 0.0002) and lesion pain (p < 0.01), and more rapid lesion scabbing (p < 0.004) and lesion healing (p < 0.04). The most common adverse reaction was a low incidence of peripheral vein irritation; no serious toxicity could be definitely attributed to acyclovir treatment even in these seriously ill patients. Intravenous acyclovir offers both safe and effective treatment for mucocutaneous herpes simplex virus infection in the immunocompromised host.

Original languageEnglish (US)
Pages (from-to)229-235
Number of pages7
JournalThe American Journal of Medicine
Volume73
Issue number1 PART 1
DOIs
StatePublished - Jul 20 1982

Bibliographical note

Funding Information:
From the Department of Medicine, University of Washington School of Medicine and the Fred Hutchinson Cancer Research Center, Seattle, Washington; Departmants of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota; Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Medicine, Duke University School of Medicine, Durham, North Carolina; Laboratory of Clinical Microbiology, Sidney Farber Cancer Institute, Boston, Massachusetts: and Burroughs Wellcome Co., Research Triangle Park, North Carolina. This work was supported by grants from the Burroughs Wellcome Co. and grants CA 18029, Al 15689, Al 07044, AM 13083. AM 18883, CA 19589, CA 06973 and CA 15396 from the National Institutes of Health. Requests for reprints should be addressed to Dr. Joel D. Meyers, Program in infec- tious Diseases, Fred Hutchinson Cancer Research Center, 1124 Columbia Street, Seattle, Washington 98104.

Fingerprint

Dive into the research topics of 'Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host'. Together they form a unique fingerprint.

Cite this